1 / 98

Thyroid Disorders

Thyroid Disorders. T₃: Triiodothyronine T₄: Thyroxine. I. Hyperthyroidism ( Thyrotoxicosis ). Characterized by hypermetabolism of all body systems & increased serum levels of free thyroid hormones. More common in women. Rare in children Less common than hypothyroidism.

xanti
Download Presentation

Thyroid Disorders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Thyroid Disorders T₃: Triiodothyronine T₄: Thyroxine

  2. I. Hyperthyroidism (Thyrotoxicosis) • Characterized by hypermetabolism of all body systems & increased serum levels of free thyroid hormones. • More common in women. • Rare in children • Less common than hypothyroidism

  3. Thyroid Storm: • Exaggerated form of hypertoxicosis. • Medical emergencyPrompt treatment • May be precipitated by : -Infection -Trauma - Surgery -Embolism -Diabetic ketoacidosis -Others…

  4. Subclinical Hyperthyroidism: • Suppressed TSH level w/ NL thyroid hormone levels. • Symptoms are NOT always present esp. in elderly. • Pathophysiology: See p. 987-990

  5. Treatment Goals of Hyperthyroidism: • Reverse S/S, normalize thyroid hormone levels, min. deleterious S/Es of T₄ on organ systems, prevent thyroid storm, & improve overall functional capacity. • Reverse hyperthyroid complaints. • Reverse hyperthyroid physical findings. • Normalize free T₄, T₃, & TSH levels. • Reduce goiter size.

  6. Improve cardiac function & prevent systemic embolism. 7) Preserve bone density& prevent osteoporosis. 8) Improve emotional well being& quality of life. 9) Support placenta development & maintenance of pregnancy. 10) Promote normal growth, & physical & mental development.

  7. Causes of Hyperthyroidism: (table38.3 p.993) • Graves disease: -Autoimmune -May occur w/ other autoimmune disorders. -Most common cause -Charact. by hyperthyroid. & one or more of the following: * Goiter * Exophthalmos * Dermopathy

  8. 2) Toxic Nodules: -Single & multinodular -Autonomous: independent of TSH control. -May be caused by: *Iodine deficiency *Genetic abnormality *Immune System

  9. 3) SubacuteThyroiditis: - Inflammatory thyroiditis, i.e.Postpartum(PPT), viral (i.e. de Quervain). - Hyperthyroid. from leakage of thyroid hormones into circulation due to inflamed gland & NOT increased synthesis. -Hypothyroidism may follow.

  10. 4) Drug Induced: -Iodides (Jod-Basedow), Amiodarone, Lithium, Cytokines 5) Neonatal thyrotoxicosis (Graves): -Transplacental passage of TRab causing the infant to be extremely ill w/in delivery hrs. -Self-limiting.

  11. 6) Hashitoxicosis: -Hyperthyroid phase of Hashimoto thyroiditis 7) T₃ toxicosis: -Preferential secretion of T₃, often precedes T₄ toxicosis. 8) Tumors: -Secretion of thyroid stimulating substances. 9) Factitious: -Self-administration of levothyroxine

  12. Clinical Presentation & Diagnosis: - Characteristics of Graves Dz. p.997 Table 38.6 -SxS of Hyperthyroidism & Hypothyroidism p.995 Table 38.4 - Thyroid Function Tests (TFTs) p.987-988

  13. Diagnosis of Hyperthyroidism : • Confirmed w/ abnormally high levels of FT₄ or TT₃ & undetectable TSH. 2) +Antibodies, opthalmopathy, or dermopathy confirms the diagnosis of Graves. 3) RAIU in Graves but is NOT cost-effective 4) TT₃ & + TRab are essential for atypical presentation, i.e. in elderly.

  14. 5) SubacuteThyroiditis (PPT,…), Diagnosis is confirmed by: *Low or undetectable RAIU. * TH levels. *Suppressed or undetectable TSH level. * ESR * No Thyroid Ab. * Leukocytosis, gland tenderness, & S/S of hyper or hypothyroidism.

  15. Therapeutic Plan: (table 38.7, p.998-999) • Major Modalities for Management of Hyperthyroidism, include: 1) Thioamides 2) RAI 3) Surgery ** Treatment must be individualized, each has advantages & limitations **Effective Treatment Selection p.1000, Fig.38.3

  16. Treatment Adjuncts: • Iodides • Iodinated Contrast Media • K Perchlorate • Adrenergic Antagonists • Corticosteroids • Cholestyramine • Rarely Li

  17. In U.S., RAI is most commonly used except in younger pts. for whom Thioamides are used. • In Europe & Japan, Thioamides are the TOC. • Surgery is the last choice unless there is: *Obstructive symptoms or* Malignancy

  18. Treatment is individualized a/c to: 1. Etiology 2. Pt. age 3. Goiter size 4. Thyroid & Medical complications 5. Social & Economic issues

  19. Graves: All 3 methods are effective but pt. or Dr. may prefer meds. over RAI or surgery. • TMG: RAI or surgery > effective than meds., but factors as medical condition or pt. or Dr. may prefer RAI use over surgery. 3.Transient Treatment : may be used when the disease is self-limited, i.e.: * SubacuteThyroiditis (PPT,…) *Neonatal Graves *Drug-Induced Hyperthroidism

  20. In Uncomplicated Graves esp. in children, Thioamidesare preferred until remission. • Thioamides: - Do NOT destroy the gland - Control the disease - Chronic thyroid replacement may not be necessary (not like w/ RAI or Surg.), however, hypothyroid. may still develop eventually.

  21. If RAI or Surgery is selected, most older pts. & all severely ill thyrotoxic pts. should be pretreated w/ Thioamides. • Pretreatment: • Depletes gland of stored hormones. • Hypermetabolic rate. • Prevents leakage of hormone from gland after RAI or during surgery preventing thyroid storm.

  22. Optimal Tx of hyperthyroidism in Graves opthalmopathy is unresolved. • Some prefer RAI or surgery (<desirable) to remove the antigen source (gland) & > effective than thioamides to prevent progressive opthalmopathy. • Prophylactic systemic corticosteroid (e.g., Prednisone 30-40mg daily starting within a few days of RAI & cont. for ~2-3 wks. to prevent further progression of opthalmopathy in pts. w/ re-existing cases. • Hypothyroidism can aggravate preexisting eye complaints. • Hyperthyroidism control & hypothyroidism prevention are essential to prevent progression of opthalmopathy.

  23. Single or Toxic multinodular Dz.: • Best managed with definitive Tx, i.e. RAI or surgery, because spontaneous remission is unlikely. • Hyperthyroid Children: The usual Tx choices are Thioamides & subtotal thyroidectomy, although all 3 methods have been used.

  24. In Pregnancy: • Hyperthyroidism is difficult to manage. • Spontaneous remission may occur because of the decrease in TRab. • Antithyroid meds. are often NOT necessary. • If untreated, complications may occur. • RAI & Iodides are Contraindicated in pregnancy. • Surgery in 2nd trimester is an option.

  25. Neonatal Graves: • Infants extremely ill w/in delivery hrs. • Supportive measures, i.e. *sedation *O₂ *Fluids/Electrolytes • Short-term (temporary) thioamides, iodides, or beta blockers since it is self-limiting. • Symptoms disappear in 1-2 months, therefore, withdraw antithyroids at this time.

  26. SubacuteThyroiditis: • Self-limiting (common spontaneous recovery). • Symptomatic treatment: *Heat *Rest *NSAIDs *Beta-blockers * Thioamides are NOT effective since it is due to thyroid hormone leakage & NOT increase in TH synthesis.

  27. Cont. SubacuteThyroiditis: • Corticosteroids are indicated for severe inflammation if NSAIDs are ineffective. • In Hypothyroid phase: Transient thyroid replacement is used to suppress further TSH stimulation to damaged gland & treat hypothyroid symptoms.

  28. Treatment: Fig.38.3 p.1000 • Pharmacotherapy: • Thioamides: *Long-term 1⁰ therapy for Graves esp. in children & adolescents. *Transiently used to reduce TH levels before definitive therapy w/ RAI or surgery. *TOC for small goiters & mild dz. For whom a high remission rate is likely.

  29. Advantages: • Potential for remission without gland damage. • Limitations: 1.Non-adherence 2.Strict parental & physician supervision in kids. 3.Low success rates. 4. Risk of ADRs.

  30. Thioamides: 1. Methimazole 2. Propylthiouracil (PTU) • They prevent TH synthesis. • PTU (Not Methimazole) inhibits peripheral deiodination of T₄ to T₃. • They suppress TSH receptor Ab level by unknown immunosuppressive MOA.

  31. Thioamides Selection: • Pharmacologic Differences: ** Methimazole is preferred over PTU, because: 1. Single daily dose ( PTU Q6-8H) 2. More potent than PTU 3. Less toxic than PTU @ low doses. 4. Less costly. ** Both are equally effective @ equipotent doses.

  32. PTU is preferred over methimazole in pts. w/ **Thyroid Storm Or **Severe Hyperthyroidism Because: • PTU blocks the conversion of T₄ to T₃ peripherally. • PTU may have faster OA. *PTU is preferred in pregnancy because methimazole may be associated w/ congenital skin defect ( NOT sufficiently supported & has been used in pregnancy without deleterious effects). *Both can be used safely in pregnancy *PTU is preferred in lactation because insignificant amounts are secreted in the breast milk. *Generally,Methimazole is the thioamide of choice EXCEPT in the situations mentioned above where PTU is preferred , or if the patient cannot tolerate methimazole.

  33. No IV preparations of thioamides. • It usually takes 6-8wks before SxS subside & TH normalize. • Initial dose: Methimazole 30-40 mg/d orally or PTU 300-400mg/d in 3-4 divided doses. Tapering down dose only after SxS subside: **Initial dose is reduced gradually by 1/3 each month until daily M.D. of 5-15mg methimazole or 50-150mg PTU is reached.

  34. Baseline FT₄ & WBC count w/ differ. should be done before thioamides are started because agranulocytosis can be induced by thioamides & also hyperthyroidism is associated w/ relative reduction of neutrophils. • FT₄ or FT₄I & TSH should be monitored routinely @ 4-8 wks after starting Tx & after any dose change. • Once stable thioamide M.D. is reached, TFTs should be monitored Q 2-4 or Q3-6 months.

  35. Recommended duration of Tx for Graves is emperic: Generally 12-18 months. • 12 months is the minimum Tx duration recommended to maximize remission potential. • Longer durations can be used if NO ADRs. • Some pts. remain in remission & others relapse ????

  36. Toxic Reactions: • PruriticMaculopapular Skin Rash: Most common & treated w/ antihistamines. • Hepatatis: *If LFTs normalize w/in 3 months of dose reduction, NO need to discontinue PTU. *If there is clinical evidence of hepatitis, D/C PTU immediately. * Routine monitoring of LFTs is required for: 1. Pts. w/ liver dz. history. 2. Hepatitis risk factors, i.e. alcoholism

More Related